Clinical trials: Glucocorticoid-induced Beta-cell Dysfunction
Glucocorticoid-induced Glucometabolic Abnormalities, Glucocorticoid-induced Beta-cell Dysfunction
PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide
The purpose of this study is to explore whether the GLP-1 receptor agonist exenatide, may prevent glucocorticoid-induced glucometabolic abnormalities and beta-cell dysfunction in healthy subjects.
- Trial name
- PREDEX (NCT00744224)
- Testing
- Prednisolone, Prednisolone and Exenatide
- Where
- Netherlands
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc
Diabetes Mellitus, Steroid Diabetes
Sitagliptin Prophylaxis for Glucocorticoid-Induced Impairment of Glucose Metabolism in Males With the Metabolic Syndrome
The investigators will assess whether the DPP-inhibitor sitagliptin will ameliorate glucocorticoid-induced impairment of glucose metabolism and beta-cell dysfunction and thus could be used as a prophylaxis for…
- Conditions
- Diabetes Mellitus, Steroid Diabetes, Glucocorticoid-induced Diabetes, Beta-cell Function
- Trial name
- SPHINX (NCT00721552)
- Testing
- Sitagliptin 100 mg, Prednisolone 30 mg
- Where
- Netherlands
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- Amsterdam UMC, location VUmc